SOLTI-1805 TOT-HER3 Study Concept: A Window-of-Opportunity Trial of Patritumab Deruxtecan, a HER3 Directed Antibody Drug Conjugate, in Patients With Early Breast Cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed, 29 citations in OpenAlex.

1. Beyond conventional therapies: the evolution of targeted agents and immunotherapies in triple-negative breast cancer.Acta pharmacologica Sinica · 2026
   Review
2. HER3-targeting Antibody-drug Conjugates Therapy for Solid Tumors: Recent Advances and Future Potentials.Current medicinal chemistry · 2026
   Review
3. HER2-Targeted Antibody-Drug Conjugate Toxicities in Breast Cancer.Cancer medicine · 2025
   Review
4. Patritumab deruxtecan in breast cancer treatment: a drug evaluation.Future oncology (London, England) · 2025
   Review
5. Determinants of long-term response to patritumab deruxtecan in breast cancer patient-derived xenografts.NPJ precision oncology · 2025
   Article
6. Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies.MedComm · 2024
   Review
7. Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response.Nature communications · 2024
   Article
8. The Evolving Paradigm of Antibody-Drug Conjugates Targeting the ErbB/HER Family of Receptor Tyrosine Kinases.Pharmaceutics · 2024
   Review
9. A prospective study of HER3 expression pre and post neoadjuvant therapy of different breast cancer subtypes: implications for HER3 imaging therapy guidance.Breast cancer research : BCR · 2024
   Article
10. mTOR inhibitor introduce disitamab vedotin (RC48-ADC) rechallenge microtubule-chemotherapy resistance in HER2-low MBC patients with PI3K mutation.Frontiers in oncology · 2024
    Review
11. Targeted radionuclide therapy for head and neck squamous cell carcinoma: a review.Frontiers in oncology · 2024
    Review
12. Antibody-Drug Conjugates in HR+ Breast Cancer: Where Are We Now and Where Are We Heading?Journal of clinical medicine · 2023
    Review
13. Genetic Testing Enhances the Precision Diagnosis and Treatment of Breast Cancer.International journal of molecular sciences · 2023
    Review
14. Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations.EClinicalMedicine · 2023
    Review
15. Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions.International journal of molecular sciences · 2023
    Review
16. Human epidermal growth factor receptor 3 serves as a novel therapeutic target for acral melanoma.Cell death discovery · 2023
    Article
17. Patient perspectives on window of opportunity clinical trials in early-stage breast cancer.Breast cancer research and treatment · 2022
    Article
18. Antibody-drug conjugates: beyond current approvals and potential future strategies.Exploration of targeted anti-tumor therapy · 2022
    Review
19. HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer.Cancer journal (Sudbury, Mass.)
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

26 authors at 13 institutions in 2 countries.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as